CRESCENT BIOPHARMA INC

Insider sales at Crescent Biopharma are routine tax‑cover moves, not a sign of declining confidence – backed by FDA approval, EMA access, and strong Phase II data.

Investors should watch Crescent Biopharma’s June 22 insider sales—under Rule 10b5‑1, a coordinated move that may signal upcoming capital‑raising or strategic shifts while the company’s strong cash, hematology pipeline and regulatory approvals offer …